

**Interaction Report**

**Report ID:**  
**Date Produced:** 06 December 2022

**Hepatitis Treatment****Co-medications**

Ombitasvir/Paritaprevir/r + Dasabuvir

Carbamazepine

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see [www.hep-druginteractions.org](http://www.hep-druginteractions.org).

**Description of the interactions****Drugs that should not be coadministered (RED)****Ombitasvir/Paritaprevir/r + Dasabuvir + Carbamazepine**

Coadministration is contraindicated. Carbamazepine is a substrate and inducer of CYPs 3A4, 2C8 and 1A2. Ombitasvir/paritaprevir/ritonavir + dasabuvir exposures show significant decreases when administered with carbamazepine (ombitasvir C<sub>max</sub> and AUC both decreased by 31%; paritaprevir C<sub>max</sub> and AUC decreased by 66% and 70%) which may lead to virologic failure.